Therapeutic Area

Neuroblastoma

Therapeutic area intelligence for Neuroblastoma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 2

Companies

Aminex Therapeutics, Inc. →

United Therapeutics →

Assets

Dinutuximab →

Phase →

Recent signals(2)

ClinicalJune 20, 2026

Phase 1 Study of AMXT 1501 and DFMO for Neuroblastoma and CNS Tumors

A clinical trial is underway to evaluate the combination of AMXT 1501 and eflornithine (DFMO) for treating neuroblastoma and CNS tumors.

ClinicalJune 17, 2026

Phase III Trial of Dinutuximab in High-Risk Neuroblastoma Shows Promise

A phase III trial is evaluating the efficacy of dinutuximab combined with standard chemotherapy and surgery for high-risk neuroblastoma in children.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.